What happened

Actions of Organic Provention (NASDAQ: PRVB) collapsed 28.8% at market close on Friday. The huge drop came after a U.S. Food and Drug Administration (FDA) advisory committee voted 10-7 in favor of the recommendation to approve teplizumab to delay type 1 diabetes.

So what

Investors were clearly expecting a more lopsided vote for teplizumab after FDA backgrounders looked fairly positive on Provention’s clinical data. These documents indicated that the company’s TN-10 clinical study “successfully demonstrated the therapeutic effect of teplizumab in delaying the diagnosis of T1D.”

Image source: Getty Images.

However, the FDA’s Endocrinology and Metabolic Drugs Advisory Committee was not as convinced of the investigational drug. Some committee members expressed reservations about the small size of the pivotal study conducted by Provention. They were also concerned that patients would not be followed up after being diagnosed with type 1 diabetes.

It is possible that the relatively narrow vote may increase the chances that teplizumab will not be approved by the FDA. However, the agency generally accepts the recommendations of the advisory committee.

Now what

What’s next for the biotechnology stock? The FDA is expected to announce its decision on approving teplizumab by July 2.

10 stocks we like better than Provention Bio Inc
When investment geniuses David and Tom Gardner have stock advice, he can pay to listen. After all, the newsletter they’ve been distributing for over a decade, Motley Fool Fellowship Advisor, has tripled the market. *

David and Tom have just revealed what they believe to be the ten best stocks for investors to buy now … and Provention Bio Inc was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* Stock Advisor returns as of May 11, 2021

Keith Speights has no position in any of the listed securities. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

Leave a Reply

Your email address will not be published.